Holen Sie sich die Stockscreener-App
58.18
0.60%
-0.35
Handel nachbörslich:
58.18
Schlusskurs vom Vortag:
$58.53
Offen:
$58.5
24-Stunden-Volumen:
2.54M
Relative Volume:
0.71
Marktkapitalisierung:
$25.79B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
30.47
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
+3.10%
1M Leistung:
+8.34%
6M Leistung:
+47.10%
1J Leistung:
+64.03%
1-Tages-Spanne:
$58.12
$59.44
1-Wochen-Bereich:
$54.95
$59.44
52-Wochen-Spanne:
$34.08
$59.44
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
58.18 | 25.94B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma declares $0.235 dividend - MSN
Royalty Pharma Maintains Quarterly Dividend at $0.235 a Share, Payable on Sept. 10 to Shareholders of Record on Aug. 14 - marketscreener.com
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com Canada
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share - Quiver Quantitative
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield - StreetInsider
Royalty Pharma plc Declares Third Quarter 2026 Dividend, Payable on September 10, 2026 - marketscreener.com
Royalty Pharma stock hits all-time high at 58.85 USD By Investing.com - Investing.com South Africa
RPHC6166012 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's Why - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
RPHC5824522 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma to announce Q2 2026 financial results on August 5 - scanx.trade
Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results - Stock Titan
RPHC5222527 Bond Profile — Key Metrics - TradingView
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 - Yahoo Finance
US78081BAN3 Bond Coupon Profile — Rate & Payments - TradingView
US78081BAN3 Bond Risk Profile - TradingView
Royalty Pharma PLC $RPRX Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Calamos Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824522 Bond Risk Profile - TradingView
RPHC5824522 Bond Profile — Key Metrics - TradingView
Calamos Wealth Management LLC Acquires New Shares in Royalty Pharma PLC $RPRX - MarketBeat
US78081BAQ6 Bond Coupon Profile — Rate & Payments - TradingView
Canal Insurance CO Acquires Shares of 20,000 Royalty Pharma PLC $RPRX - MarketBeat
RPHC5237891 Bond Profile — Key Metrics - TradingView
RPHC5237891 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237891 Bond Risk Profile - TradingView
US78081BAQ6 Bond Risk Profile - TradingView
US78081BAQ6 Bond Profile — Key Metrics - TradingView
Royalty Pharma (RPRX) Stock Analysis: A Strategic Look At Growth And Valuation Potential - DirectorsTalk Interviews
Royalty Pharma Q1 2026 earnings preview - MSN
World Investment Advisors Sells 48,485 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX is Torray Investment Partners LLC's Largest Position - MarketBeat
Hsbc Holdings PLC Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Morgan Stanley’s 22nd Annual Global Healthcare Conference summary - Quartr
Royalty Pharma (RPRX) Citi Annual Global Healthcare Conference 2025 Summary - Quartr
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again - Yahoo! Finance Canada
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice - Yahoo! Finance Canada
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX) - Sahm
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
RPRX or ACAD: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
Royalty Pharma (RPRX) Could Be 2% Undervalued On Russell 1000 Defensive Index Addition - Sahm
Y Intercept Hong Kong Ltd Grows Stake in Royalty Pharma PLC $RPRX - MarketBeat
Swedbank AB Sells 355,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma stock hits all-time high at 58.02 USD By Investing.com - Investing.com South Africa
Royalty Pharma stock hits all-time high at 58.02 USD - Investing.com
Royalty Pharma plc (RPRX) Stock Analysis: Navigating the Biotech Sector with Robust Revenue Growth - DirectorsTalk Interviews
Royalty Pharma PLC $RPRX Shares Sold by Inspire Investing LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.71%
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):